Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
In the Guidance for Industry from the Food and Drug Administration in 2008, excess cardiovascular risk should be ruled out in trials of all new antidiabetic drugs; however, relatively few studies have focused on cardiovascular safety with antidiabetic drug use. We aimed to examine mortality and card...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5444626?pdf=render |
| _version_ | 1811194955012505600 |
|---|---|
| author | Gyeongsil Lee Seung-Won Oh Seung-Sik Hwang Ji Won Yoon Sungchan Kang Hee-Kyung Joh Hyuktae Kwon Jeehyun Kim Danbee Park |
| author_facet | Gyeongsil Lee Seung-Won Oh Seung-Sik Hwang Ji Won Yoon Sungchan Kang Hee-Kyung Joh Hyuktae Kwon Jeehyun Kim Danbee Park |
| author_sort | Gyeongsil Lee |
| collection | DOAJ |
| description | In the Guidance for Industry from the Food and Drug Administration in 2008, excess cardiovascular risk should be ruled out in trials of all new antidiabetic drugs; however, relatively few studies have focused on cardiovascular safety with antidiabetic drug use. We aimed to examine mortality and cardiovascular risk using a network meta-analysis. We searched the Medline, Embase, Cochrane, and ClinicalTrials.gov registry databases in March 2016 to identify randomized controlled trials reporting cardiovascular risk with the following oral antidiabetic drugs: metformin, sulfonylureas, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP4) inhibitors, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. We assessed the differences in the risks of all-cause mortality, cardiovascular-related mortality, acute coronary syndrome (ACS), and myocardial infarction (MI) among antidiabetic drugs with fixed effect models for direct pairwise comparisons and Bayesian network meta-analyses to integrate direct and indirect comparisons. Of the 101,183 patients in 73 randomized controlled trials, 3,434 (3.4%) died. The relative risks of all-cause mortality with SGLT2 inhibitor use were 0.68 (95% credible interval: 0.57-0.80), 0.74 (0.49-1.10), 0.63 (0.46-0.87), 0.71 (0.55-0.90), and 0.65 (0.54-0.78), compared with placebo, metformin, sulfonylurea, TZD, and DPP4 inhibitor, respectively. The relative risks of cardiovascular-related mortality with SGLT2 inhibitor use were 0.61 (0.50-0.76), 0.81(0.36-1.90), 0.52(0.31-0.88), 0.66(0.49-0.91), and 0.61(0.48-0.77), compared with placebo, metformin, sulfonylurea, TZD, and DPP4 inhibitor, respectively. The relative risks of ACS with SGLT2 inhibitor use was consistent with that of all-cause mortality. SGLT2 inhibitor use was associated with a lower risk of ACS than the other OADs and placebo. The relative risks of MI with SGLT2 inhibitor use were 0.77 (0.63-0.93) and 0.75 (0.60-0.94), compared with placebo and DPP4 inhibitor, respectively. The currently available data provide the evidence of cardiovascular benefit from use of SGLT2 inhibitors to patients with type 2 diabetes, although additional results from ongoing studies will be pivotal. |
| first_indexed | 2024-04-12T00:35:57Z |
| format | Article |
| id | doaj.art-1da750cb2bc44309a5b8e66f59cede9c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T00:35:57Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1da750cb2bc44309a5b8e66f59cede9c2022-12-22T03:55:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017764610.1371/journal.pone.0177646Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.Gyeongsil LeeSeung-Won OhSeung-Sik HwangJi Won YoonSungchan KangHee-Kyung JohHyuktae KwonJeehyun KimDanbee ParkIn the Guidance for Industry from the Food and Drug Administration in 2008, excess cardiovascular risk should be ruled out in trials of all new antidiabetic drugs; however, relatively few studies have focused on cardiovascular safety with antidiabetic drug use. We aimed to examine mortality and cardiovascular risk using a network meta-analysis. We searched the Medline, Embase, Cochrane, and ClinicalTrials.gov registry databases in March 2016 to identify randomized controlled trials reporting cardiovascular risk with the following oral antidiabetic drugs: metformin, sulfonylureas, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP4) inhibitors, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. We assessed the differences in the risks of all-cause mortality, cardiovascular-related mortality, acute coronary syndrome (ACS), and myocardial infarction (MI) among antidiabetic drugs with fixed effect models for direct pairwise comparisons and Bayesian network meta-analyses to integrate direct and indirect comparisons. Of the 101,183 patients in 73 randomized controlled trials, 3,434 (3.4%) died. The relative risks of all-cause mortality with SGLT2 inhibitor use were 0.68 (95% credible interval: 0.57-0.80), 0.74 (0.49-1.10), 0.63 (0.46-0.87), 0.71 (0.55-0.90), and 0.65 (0.54-0.78), compared with placebo, metformin, sulfonylurea, TZD, and DPP4 inhibitor, respectively. The relative risks of cardiovascular-related mortality with SGLT2 inhibitor use were 0.61 (0.50-0.76), 0.81(0.36-1.90), 0.52(0.31-0.88), 0.66(0.49-0.91), and 0.61(0.48-0.77), compared with placebo, metformin, sulfonylurea, TZD, and DPP4 inhibitor, respectively. The relative risks of ACS with SGLT2 inhibitor use was consistent with that of all-cause mortality. SGLT2 inhibitor use was associated with a lower risk of ACS than the other OADs and placebo. The relative risks of MI with SGLT2 inhibitor use were 0.77 (0.63-0.93) and 0.75 (0.60-0.94), compared with placebo and DPP4 inhibitor, respectively. The currently available data provide the evidence of cardiovascular benefit from use of SGLT2 inhibitors to patients with type 2 diabetes, although additional results from ongoing studies will be pivotal.http://europepmc.org/articles/PMC5444626?pdf=render |
| spellingShingle | Gyeongsil Lee Seung-Won Oh Seung-Sik Hwang Ji Won Yoon Sungchan Kang Hee-Kyung Joh Hyuktae Kwon Jeehyun Kim Danbee Park Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PLoS ONE |
| title | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. |
| title_full | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. |
| title_fullStr | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. |
| title_full_unstemmed | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. |
| title_short | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. |
| title_sort | comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity a network meta analysis |
| url | http://europepmc.org/articles/PMC5444626?pdf=render |
| work_keys_str_mv | AT gyeongsillee comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT seungwonoh comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT seungsikhwang comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT jiwonyoon comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT sungchankang comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT heekyungjoh comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT hyuktaekwon comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT jeehyunkim comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis AT danbeepark comparativeeffectivenessoforalantidiabeticdrugsinpreventingcardiovascularmortalityandmorbidityanetworkmetaanalysis |